Retinal vein occlusion

Summary

Retinal vein occlusion (MONDO:0006951) is a disease and 152 clinical trials. Top therapeutic interventions include ranibizumab, aflibercept, and faricimab. A subtype of retinal vascular occlusion — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 152

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	retinal vein occlusion
Mondo ID	MONDO:0006951
EFO	EFO:1001157
MeSH	D012170
DOID	DOID:1727
NCIT	C34981
SNOMED CT	46085004
UMLS	C0035328
MedGen	19763
MedDRA	10038907
Is cancer (heuristic)	no

Also known as: retinal vein occlusion

Disease family

This is a subtype of retinal vascular occlusion. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal vascular disorder › retinal vascular occlusion › retinal vein occlusion

Related subtypes (1): retinal artery occlusion

Subtypes (3): occlusion of tributary of retinal vein, partial retinal vein occlusion, central retinal vein occlusion

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 7 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Aflibercept	Approved (phase 4)
Aspirin	Phase 3 (in late-stage trials)
Bevacizumab	Phase 3 (in late-stage trials)
Brolucizumab	Phase 3 (in late-stage trials)
Parnaparin	Phase 3 (in late-stage trials)
Ranibizumab	Phase 3 (in late-stage trials)
Triamcinolone	Phase 3 (in late-stage trials)
Triamcinolone Acetonide	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Anecortave Acetate, Betamethasone, Conbercept, Dexamethasone, Fasudil, Niacin, Pegaptanib Sodium, Prednisolone Acetate.

Clinical trials & evidence

Clinical trials

Clinical trials: 152.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	73
PHASE4	19
PHASE3	19
PHASE2	15
PHASE1	9
PHASE1/PHASE2	8
PHASE2/PHASE3	5
EARLY_PHASE1	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07133438	PHASE4	RECRUITING	Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment
NCT07456826	PHASE4	ENROLLING_BY_INVITATION	Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
NCT01027481	PHASE4	COMPLETED	Ranibizumab in Patients With Branch Retinal Vein Occlusion
NCT01085734	PHASE4	COMPLETED	Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion
NCT01427751	PHASE4	COMPLETED	Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
NCT01573572	PHASE4	COMPLETED	Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
NCT01580020	PHASE4	COMPLETED	Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO
NCT01857544	PHASE4	UNKNOWN	Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy
NCT01903720	PHASE4	COMPLETED	A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
NCT02140411	PHASE4	COMPLETED	Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
NCT02503540	PHASE4	COMPLETED	Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
NCT03056079	PHASE4	UNKNOWN	Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept
NCT03056092	PHASE4	UNKNOWN	Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab
NCT03908307	PHASE4	COMPLETED	Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China
NCT03918590	PHASE4	UNKNOWN	Post Intravitreal Injection Topical NSAID vs. Patching
NCT04062370	PHASE4	UNKNOWN	Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion
NCT04563299	PHASE4	TERMINATED	Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections
NCT04707625	PHASE4	TERMINATED	Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment
NCT06416241	PHASE4	COMPLETED	Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion
NCT00000131	PHASE3	COMPLETED	Central Vein Occlusion Study (CVOS)
NCT00105027	PHASE3	COMPLETED	The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study
NCT00106132	PHASE3	COMPLETED	Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage
NCT00168298	PHASE3	COMPLETED	A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
NCT00168324	PHASE3	COMPLETED	A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
NCT00485836	PHASE3	COMPLETED	A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)
NCT00486018	PHASE3	COMPLETED	A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
NCT00493064	PHASE2/PHASE3	COMPLETED	To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions
NCT00517257	PHASE3	UNKNOWN	Atorvastatin for the Treatment of Retinal Vein Occlusion
NCT00732927	PHASE3	TERMINATED	Parnaparin vs Aspirin in the Treatment of Retinal Vein Occlusion
NCT00805064	PHASE3	COMPLETED	Combined Triple Procedure in Retinal Vein Occlusion (RVO)
NCT00942864	PHASE3	COMPLETED	Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)
NCT00970957	PHASE3	COMPLETED	Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion
NCT01012973	PHASE3	COMPLETED	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
NCT01198327	PHASE3	COMPLETED	Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion
NCT01377597	PHASE3	COMPLETED	Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion
NCT01449682	PHASE3	COMPLETED	Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.
NCT01635803	PHASE2/PHASE3	UNKNOWN	Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)
NCT01790685	PHASE2/PHASE3	COMPLETED	Ozurdex for Retinal Vein Occlusion Study (ORVO Study)
NCT02980874	PHASE3	TERMINATED	Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
NCT03203447	PHASE3	TERMINATED	Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RANIBIZUMAB	4	19
AFLIBERCEPT	4	5
FARICIMAB	4	3
BETAMETHASONE	4	2
DEXAMETHASONE	4	2
MINOCYCLINE	4	2
PREDNISOLONE ACETATE	4	2
BEVACIZUMAB	4	1
DEXAMETHASONE SODIUM PHOSPHATE	4	1
FLUOCINOLONE ACETONIDE	4	1
FLUORESCEIN	4	1
LOTEPREDNOL ETABONATE	4	1
MECOBALAMIN	4	1
NEPAFENAC	4	1
NIACIN	4	1
PEGAPTANIB SODIUM	4	1
PROPARACAINE	4	1
TRIAMCINOLONE	4	1
TRIAMCINOLONE ACETONIDE	4	1
CONBERCEPT	3	2
TARCOCIMAB TEDROMER	3	2
ANECORTAVE ACETATE	3	1
FASUDIL	3	1
MAXACALCITOL	3	1
PARNAPARIN	3	1
RELMAPIRAZIN	3	1
ANNEXIN A5	2	1
METHYLCOBALAMIN	2	1
RAZUPROTAFIB	2	1
CHEMBL4781942	0	1